GlassScriptPhysician profile
Mark B Bromberg
NPI 1164517009
$265,286.10
in general payments reported to CMS, 2019-2025
14 companies · $80K in 2025
The $80K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $23K · 2021: $22K · 2022: $55K · 2023: $24K · 2024: $39K · 2025: $80K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $65K · Consulting Fee: $65K · Travel and Lodging: $10K · Food and Beverage: $2,931 · Education: $8.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,257.26 |
| Consulting Fee | $64,825.00 |
| Travel and Lodging | $10,458.75 |
| Food and Beverage | $2,931.08 |
| Education | $8.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $139,936.09 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Grifols USA, LLC | $77,580.43 | 2019-2025 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $17,072.91 | 2021-2025 | Hyqvia |
| Tanabe Pharma America, INC. | $12,671.25 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $10,586.93 | 2019-2025 | Ultomiris |
| Shire North American Group INC | $7,014.58 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2024 | Tremfya |
| Acorda Therapeutics, INC | $110.39 | 2019 | |
| Integra Lifesciences Corporation | $102.94 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $85.58 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bromberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.